Q1 2026 · 13F-HR
Catalio Capital Management, LPholdings as filed
Filed 2026-05-15 · accession 0001958125-26-000003
The Brief · Catalio Capital Management, LP · Q1 2026
AI · grounded in 13F
Catalio Capital Management, LP closed its position in BridgeBio Oncology Therapeutics BBOT for a reduction of $31.4M. The fund established new positions in BridgeBio Pharma Inc BBIO for $32.1M, Definium Therapeutics Inc DFTX for $19.6M, and Incyte Corp INCY for $17.1M. Other significant exits included Eli Lilly & Co LLY at $27.9M and Johnson & Johnson JNJ at $25M. The fund also increased its share counts in UltraGenyx Pharmaceutical In RARE by 423.4% and Terns Pharmaceuticals Inc 430 by 198.7%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $47.0M | 9.82% | 560,308 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $32.1M | 6.70% | 432,014 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $29.5M | 6.17% | 129,111 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $25.5M | 5.33% | 420,727 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $24.4M | 5.09% | 1,043,670 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $22.8M | 4.77% | 163,905 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $21.6M | 4.50% | 409,031 | Common | SOLE |
| 24477V105 | DFTX | DEFINIUM THERAPEUTICS INC | $19.6M | 4.10% | 1,037,984 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $19.3M | 4.04% | 577,808 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $18.8M | 3.92% | 299,318 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $17.8M | 3.72% | 850,797 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $17.1M | 3.58% | 182,101 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $14.2M | 2.97% | 215,501 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $14.2M | 2.96% | 70,907 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $13.0M | 2.73% | 891,933 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $12.3M | 2.57% | 255,379 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $11.9M | 2.48% | 439,041 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $11.6M | 2.42% | 144,607 | Common | SOLE |
| 922967104 | MANE | VERADERMICS INC | $11.0M | 2.29% | 173,582 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $10.0M | 2.10% | 722,784 | Common | SOLE |
| 42238D107 | HTFL | HEARTFLOW INC | $9.8M | 2.05% | 403,588 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $8.6M | 1.79% | 426,551 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $8.0M | 1.68% | 491,116 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $7.9M | 1.64% | 122,978 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $7.1M | 1.48% | 294,360 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $5.3M | 1.10% | 47,193 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $5.1M | 1.07% | 282,954 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $5.1M | 1.06% | 1,639,816 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $5.0M | 1.04% | 897,709 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS | $3.2M | 0.67% | 62,019 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $3.0M | 0.63% | 580,024 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $2.8M | 0.58% | 247,767 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $2.7M | 0.56% | 83,554 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $2.6M | 0.54% | 67,285 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $2.5M | 0.53% | 84,352 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $2.5M | 0.53% | 5,491,866 | Common | SOLE |
| 44916K106 | HYPR | HYPERFINE INC | $1.4M | 0.30% | 1,320,041 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI THERAPEUTICS INC | $708,851 | 0.15% | 528,993 | Common | SOLE |
| 04650F101 | ATAI | ATAIBECKLEY INC | $696,877 | 0.15% | 196,858 | Common | SOLE |
| 81728A207 | SNSE | SENSEI BIOTHERAPEUTICS INC | $463,911 | 0.10% | 14,718 | Common | SOLE |
| 690145206 | OM | OUTSET MED INC | $454,191 | 0.09% | 118,279 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.